Consolidated quarter ended 30 Sep 2026: revenue up 187%, profit after tax still negative
MEDICAPQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated quarter ended 30 Sep 2026: revenue rose 187% to Rs 577.34 lakh from Rs 201.20 lakh a year earlier; profit after tax was a Rs 8.81 lakh loss versus a Rs 182.15 lakh loss. EBITDA margin was positive 5.8% versus negative 144.8%. Consolidated half year ended 30 Sep 2026: revenue Rs 856.04 lakh and loss after tax of Rs 232.12 lakh. Half-year operating cash flow was Rs 170.65 lakh; prior figures were restated and auditors found no issues.
Revenue growth and a near break-even quarter support sentiment, but the half-year loss of Rs 232.12 lakh keeps the near-term outlook cautious.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.